Cannabis Report
Home > Boards > US OTC > Biotechs >

Vivos Inc. (RDGL)

RDGL RSS Feed
Add RDGL Price Alert      Hide Sticky   Hide Intro
Moderator: mick, boomer, Sibware, Eltp, Popeye, Tcsxyz
Search This Board: 
Last Post: 7/21/2018 1:40:49 PM - Followers: 506 - Board type: Free - Posts Today: 44

 

Vivos Inc. (OTC: RDGL)

The strategic market sector of Vivos Inc. (formerly Advanced Medical Isotope Corporation) is therapeutic isotope applications.  Currently, the Company is engaged in the development of RadioGel™, a Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.

The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics.

The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries.

What is RadioGel™?

RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor.  This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.

RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days.  This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.

What are the advantages of RadioGel™?

Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:

•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.

Half-Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.

•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, Vivos’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.

•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. Vivos’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.

•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. Vivos’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. Yttrium-90 beta-emissions travel only a short distance and have a short half-life of 2.7 days.

•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.

What is the market for RadioGel™?

Reliable sources estimate that annual sales of brachytherapy products exceed $2 billion, about half of which are in the United States. The size of the U.S. brachytherapy market for prostate cancer brachytherapy is somewhere between $90 million and $130 million per year. The market for liver and breast cancer combined is comparable.

What is Brachytherapy?

Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area.  According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.  It is estimated that the U.S. market represents approximately half of the global market.  Vivos believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers.  The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer, and 31,000 liver cancer.

Are there other markets for RadioGel™? 

March 15th, 2016, Vivos Inc. announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market. In August 2017 the subsidiary was changed and made into a separate operating division inside the Company.

The IsoPet™ Veterinary Solutions division will focus on bringing RadioGel™ yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers.

There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat.  IsoPet
Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. Initial treatments are to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.

CEO and President Dr. Mike Korenko stated: “IsoPet Solutions allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary space. We believe that RadioGel™ is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”

Dr. Alice stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as RadioGel™ Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."

What are the steps for FDA clearance?

Vivos met at the FDA offices to discuss next steps, expectations and required testing to progress towards obtaining marketing clearance for the Y-90 RadioGel™ device. The FDA and Vivos management and consulting team are working closely in order to obtain all appropriate data and benchmarks the FDA requires in order to proceed with providing final clearance for marketing the device in the United States.

August 2016, Vivos announced a partnership with IsoTherapeutics Group, a third-party radiopharmaceutical R&D company, to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel™ device. IsoTherapeutics has completed the first stage of the project, comprised of tech transfer, manufacturing and in vitro testing. The next stage, comprised of additional in vitro and in vivo testing. Upon completion of these studies, Vivos anticipates submittal (direct De Novo) for FDA clearance for full commercialization in the U.S. (see company press releases for continual updates on this evolving process).
 



Press Releases 2018 ( Change in Company name and trading symbol • Jan 2, 2018)
Jan 2, 2018,  Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL
 



Press Releases 2017 ( Change in Management & Directors Dec 2016)

Dec 20, 2016,  AMIC's Board of Directors Appoints Dr. Michael Korneko CEO and Dr. Carlton Cadwell Chairman of AMIC
Jan 11, 2017,  AMIC's New CEO Issues Letter to Shareholders
Feb 14, 2017,  AMIC's CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission
Feb 28, 2017,  AMIC's New CEO Releases Shareholder Letter Announcing and Discussing their Cancer Indication Selection to pursue FDA Approval
Mar 7, 2017,  AMIC's New CEO Releases Shareholder Letter Detailing Launch of Veterinary Oncology Division with Radiogel
Mar 23, 2017,  Update on Feline Cancer Treatment and Improvement to Financial Structure
Jul 6, 2017,  AMI Requests Pre-Submission Meeting with FDA
Jul 11, 2017,  ADMD Makes Significant Improvement to its RadioGel™ Brachytherapy Product
Jul 27, 2017,  ADMD to Host Shareholder Update Webcast with Live Q&A
Aug 2, 2017,  Advanced Medical Isotope Corp. Announces Results of Shareholder Meeting, Welcomes Two New Members of the Board of Directors
Sep 14, 2017,  Advanced Medical Isotope Corporation has its first discussions with private animal consortiums to utilize RadioGel™


Independent Analyst Research and Price Target

Sep 7, 2017, Van Leeuwenhoek Research Increases Valuation of ADMD to USD $35-$55 million USD or $0.66 - $1.00 per share


Presentation(s) from CEO & President, Dr. Mike Korenko.

2017 -  LINK HERE



STOCK SYMBOL: OTC: RDGL

COMPANY WEBSITE
FACEBOOK
TWITTER

UPDATED 8/24/2017

Outstanding Shares 51,200,000
Preffered Series A     4,000,000

 
Cannabis Report
RDGL
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
#19717   I took full advantage of this and bought Tcsxyz 03/31/15 10:54:39 AM
#34214   Most analysts believe that with approval we will Chief Slapaho 05/24/15 08:05:59 PM
#20860   With the patent they have and comparing what Tcsxyz 04/09/15 01:48:20 PM
PostSubject
#68627  Sticky Note https://www.slideshare.net/RedChip/advanced-medical-isotope-corp-presentation-83 boomer 07/17/18 02:04:50 PM
#68588  Sticky Note $RDGL:Most Recent SC13D=5.116 Million shares avrg. .01 Sibware 07/17/18 01:00:02 PM
#65430  Sticky Note Radiogel, Radiogel for Vet will be a major obesestupidmouse 08/05/17 07:15:12 PM
#63480  Sticky Note interesting eh ????? if no profit then what mick 03/05/17 12:12:44 PM
#62930  Sticky Note I know this was talked about but I Popeye 01/23/17 07:55:30 PM
#60262  Sticky Note This stock is bigger than the company. If Tcsxyz 07/27/16 08:25:42 PM
#69734   You’re talking about pretty much every bio stock Luckysevens 07/21/18 01:40:49 PM
#69733   Viking therapeutics license their drug from Ligland - Luckysevens 07/21/18 01:38:20 PM
#69732   Seems like a very quick outpatient procedure also... amazing Luckysevens 07/21/18 01:36:16 PM
#69731   LMFAO!!. This piece is 6 years old and Chief Slapaho 07/21/18 01:18:47 PM
#69729   Yeah....Suuuurrrreeeee they did.....(roll eyes) Homebrew 07/21/18 01:16:40 PM
#69728   Well this 'broke Stinky-Pinky'(your words not mine) has Fireindahole101 07/21/18 01:09:55 PM
#69727   Whereas i have confidence is my investment here, RUMe2 07/21/18 12:16:03 PM
#69726   The federal grant funding here is phenomenal. Often stayinin 07/21/18 11:56:50 AM
#69725   Fred Huch sharkey1 07/21/18 11:29:21 AM
#69724   You sell it, and right now somebody sharkey1 07/21/18 11:05:07 AM
#69723   What's that got to do with this broke Stinky-Pinky? Homebrew 07/21/18 11:00:48 AM
#69722   Just to get every one up to speed, sharkey1 07/21/18 10:57:54 AM
#69721   Interesting Vort, nice connection there. RobbinGood 07/21/18 10:56:29 AM
#69720   The 5% holders purchased immediately after this VortMax 07/21/18 10:19:31 AM
#69719   Amazing posts to help in informative & factual stayinin 07/21/18 09:54:47 AM
#69718   I see the U. DUB. med school was sharkey1 07/21/18 09:47:08 AM
#69717   Thanks I'll look up the conference for some sharkey1 07/21/18 09:40:53 AM
#69716   $RDGL "Battelle scientist gets grant to test radiogel RobbinGood 07/21/18 09:40:41 AM
#69715   $RDGL was known as the symbol, ADMD & RobbinGood 07/21/18 09:37:21 AM
#69714   and yep sharkey1, i agree with ur assessment RobbinGood 07/21/18 09:31:36 AM
#69713   sharkey1, check this, someone sent me this ?, RobbinGood 07/21/18 09:28:55 AM
#69712   Look at the dollar value yesterday, 276 K, sharkey1 07/21/18 09:15:38 AM
#69710   Your right Robbin, we've had some big time sharkey1 07/21/18 09:11:29 AM
#69709   Beautiful Day in NYC today! Rain later! But RobbinGood 07/21/18 09:10:59 AM
#69706   $RDGL Educated Investments 101: The number of Universities stayinin 07/21/18 08:38:10 AM
#69705   So true, but don't let the facts get Tcsxyz 07/21/18 08:13:26 AM
#69704   Lemonade stand could double RDGL's cash in a Homebrew 07/21/18 07:44:53 AM
#69703   LOLOL...RDGL has $16 cash, $5_Million Liabilities, and is Homebrew 07/21/18 07:41:18 AM
#69696   That interview is from Feb 18 2018, all yaboy520 07/21/18 04:38:18 AM
#69695   CeO "Undiscovered GEM in my opinion should be StockRoomBully 07/21/18 01:05:30 AM
#69694   Private clinic anxious for Vivos Data StockRoomBully 07/21/18 01:02:17 AM
#69693   6 million new cases per year catured a StockRoomBully 07/21/18 12:54:13 AM
#69692   Conservative estimate $300 MILLION MARKET POTENTIAL 3:37 StockRoomBully 07/21/18 12:50:13 AM
#69691   Radioisotope a New Tech on the Rise StockRoomBully 07/21/18 12:39:27 AM
#69690   Agreed. I’ve been adding the past 3 days. Benrnk 07/20/18 08:43:29 PM
#69689   100% agree! This one is pure gold buddy. RobbinGood 07/20/18 08:40:02 PM
#69688   That explains it. I went back and looked Benrnk 07/20/18 08:35:53 PM
#69687   Benrnk, simple mistake, should be .069, 2 ways RobbinGood 07/20/18 08:32:56 PM
#69686   Any thoughts? Benrnk 07/20/18 08:31:43 PM
#69685   This stock is going to change lives IMO, RobbinGood 07/20/18 08:19:07 PM
#69684   3:45 Benrnk 07/20/18 08:17:06 PM
#69683   Benrnk, at what time during the video did RobbinGood 07/20/18 08:13:51 PM
#69682   $RDGL THIS IS A MUST READ! EVERY SENTENCE! RobbinGood 07/20/18 08:06:45 PM
#69681   bwhahahaha hmmmm yeah, we got a cure for RobbinGood 07/20/18 08:04:54 PM
#69680   You can retrace lines if you want, this Fireindahole101 07/20/18 07:55:45 PM
#69679   SOUTHGAS, yep, all systems are a go here RobbinGood 07/20/18 07:54:24 PM
#69678   Great find and a definite must watch. I Benrnk 07/20/18 07:52:44 PM
#69677   well said PAUL, no worries here, just patience! RobbinGood 07/20/18 07:51:48 PM
#69676   StockRoomBully! THATS A MUST WATCH $RDGL VIDO! WOW!! Thanks! RobbinGood 07/20/18 07:46:18 PM
#69675   CEO:Currently in discussion with private clinic sharing Data. StockRoomBully 07/20/18 07:43:58 PM
PostSubject